Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea

被引:3
|
作者
Kim, Siin [1 ]
Kim, Hyungtae [1 ]
Kim, Eunju [1 ]
Han, Sola [1 ]
Rane, Pratik P. [2 ]
Fox, Kathleen M. [3 ]
Zhao, Zhongyun [2 ]
Qian, Yi [2 ]
Suh, Hae Sun [1 ]
机构
[1] Pusan Natl Univ, Coll Pharm, Busan, South Korea
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Strateg Healthcare Solut LLC, Aiken, SC USA
关键词
adherence; atherosclerotic cardio-vascular disease; diabetes; statin; statin intolerance; treatment pattern; LONG-TERM PERSISTENCE; STATIN THERAPY; ADHERENCE; RISK; NONADHERENCE; TERMINOLOGY; ASSOCIATION; CHOLESTEROL; MANAGEMENT; OUTCOMES;
D O I
10.1016/j.clinthera.2018.04.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: We aimed to study the utilization patterns of lipid-lowering treatment (LLT), including treatment modification, adherence, and possible statin intolerance , in patients with atherosclerotic cardiovascular disease (ASCVD) or diabetes using national claims data in South Korea. Methods: A retrospective cohort study was conducted using data from the Korean Health Insurance Review & Assessment Service claims database. Patients aged >= 18 years with > 1 outpatient pharmacy claim for a statin and/or ezetimibe dated January 1, 2012, to December 31, 2014, were identified and categorized into the following cohorts: patients with ASCVD, and patients with diabetes mellitus without ASCVD. LLT modification, adherence to index LLT, and possible statin intolerance were explored during the 12 months after the date of first prescription for a statin and/or ezetimibe. Findings: Among 1,399,872 patients who met the eligibility criteria, 807,547 (57.7%) were patients with ASCVD and 592,325 (42.3%) were patients with diabetes without ASCVD. About half of the patients had no modification in their index treatment (46.2% in the ASCVD cohort and 48.9% in the diabetes cohort), and the most common modification was permanent discontinuation (19.6% in the ASCVD cohort and 21.4% in the diabetes cohort). The mean medication possession ratios were 0.77 in the ASCVD cohort and 0.73 in the diabetes cohort and showed a decreasing trend during the 12-month follow-up period. Among patients who initiated a statin and/or ezetimibe, possible statin intolerance was observed in 53,921 patients (6.7%) in the ASCVD cohort and 42,172 patients (7.1%) in the diabetes cohort. (C) 2018 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:940 / 951
页数:12
相关论文
共 50 条
  • [1] UTILIZATION PATTERNS OF LIPID-LOWERING THERAPIES IN PATIENTS AT HIGH RISK FOR OR WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A POPULATION-BASED STUDY IN SOUTH KOREA
    Suh, H. S.
    Kim, S.
    Kim, H.
    Kim, E.
    Han, S.
    Rane, P. P.
    Fox, K. M.
    Zhao, Z.
    Qian, Y.
    VALUE IN HEALTH, 2017, 20 (09) : A628 - A629
  • [2] Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease
    Knowles, Joshua W.
    Howard, William B.
    Karayan, Lala
    Baum, Seth J.
    Wilemon, Katherine A.
    Ballantyne, Christie M.
    Myers, Kelly D.
    CIRCULATION, 2017, 135 (22) : 2204 - 2206
  • [3] Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease
    Chamberlain, Alanna M.
    Cohen, Sarah S.
    Killian, Jill M.
    Monda, Ken L.
    Weston, Susan A.
    Okerson, Ted
    AMERICAN JOURNAL OF CARDIOLOGY, 2019, 124 (07): : 995 - 1001
  • [4] Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: A population-based cohort study
    Sundboll, Jens
    Larsen, Anders Peter
    Veres, Katalin
    Adelborg, Kasper
    Sorensen, Henrik Toft
    THROMBOSIS RESEARCH, 2019, 183 : 124 - 130
  • [5] Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
    Cannon, Christopher P.
    Khan, Irfan
    Klimchak, Alexa C.
    Reynolds, Matthew R.
    Sanchez, Robert J.
    Sasiela, William J.
    JAMA CARDIOLOGY, 2017, 2 (09) : 959 - 966
  • [6] Lipid-lowering Therapy Prescription Patterns and Predictors of High Intensity Statin Prescriptions in Patients With Diabetes or Atherosclerotic Cardiovascular Disease
    Chamberlain, Alanna M.
    Cohen, Sarah S.
    Killian, Jill M.
    Monda, Keri L.
    Hedgeman, Elizabeth O.
    Weston, Susan A.
    Okerson, Ted
    CIRCULATION, 2017, 135
  • [7] Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease
    Nanna, Michael G.
    Nelson, Adam J.
    Haynes, Kevin
    Shambhu, Sonali
    Eapen, Zubin
    Cziraky, Mark J.
    Calvert, Sara B.
    Pagidipati, Neha J.
    Granger, Christopher B.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 (04) : 1243 - 1249
  • [8] PREVALENCE AND INCIDENCE OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND CARDIOVASCULAR RISK FACTORS IN SOUTH KOREA: A POPULATION-BASED STUDY
    Suh, H. S.
    Rane, P. P.
    Fox, K. M.
    Kim, H. T.
    Han, S.
    Kim, S.
    Zhao, Z.
    Qian, Y.
    VALUE IN HEALTH, 2017, 20 (05) : A264 - A264
  • [9] Comparison of Lipid-Lowering Treatment in Patients with Diabetes and/or Cardiovascular Disease
    Cohen, Sarah S.
    Chamberlain, Alanna M.
    Killian, Jill M.
    Monda, Keri L.
    Weston, Susan A.
    Okerson, Ted
    DIABETES, 2017, 66 : LB57 - LB57
  • [10] Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year
    Tran, Josephine N.
    Kao, Tzu Chun
    Caglar, Toros
    Stock, Karen M.
    Spertus, John A.
    Lew, Heidi C.
    Solow, Brian K.
    Chan, Paul S.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (08): : 901 - 908